glp-1 news 2025 october 16 Compound versions of drugs for weight loss halted by FDA Perspectives from employers on the

MapHabit is the first company to use the spared memory system through visual cues and applied behavioral analysisproven habit-building techniques that benefit people with cognitive decline

With liraglutide treatment, we did not find an increased expression of mRNAs of inflammatory cytokines (TNF- and IL-1 ) or chemokines (MCP-1 and CX3CL1) in activated PSCs

Tirzepatide (MOUNJARO) Pronounced: tir ZEP a tide / mown JAHR OH Mnemonic: Tear zeppelin (over) Mount (Kiliman)jaro Year of release: 2022 Cost: $1060 / mo FDA-approved for: Type 2 diabetes Mechanism: dual GLP-1/GIP receptor agonist Available doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg (weekly subcutaneous injection) Dynamic interactions: Glucose lowering Kinetic interactions: Delayed gastric emptying, otherwise none significant in a bubble Tirzepatide (Mounjaro) is the first twincretin for type 2 diabetes

Phentermine Use During First and Second Trimesters Associated with Fetal Stroke

Effects of Glucagon-Like Peptide-1 Receptor Agonist Exendin-4 on the Reinstatement of Cocaine-Mediated Conditioned Place Preference in Mice